Could a bladder drug calm POTS? new trial aims to find out
NCT ID NCT07585513
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether mirabegron, a drug currently used for overactive bladder, can reduce symptoms of Postural Orthostatic Tachycardia Syndrome (POTS). Thirty-six adults with confirmed POTS will receive either mirabegron or a placebo. The main goal is to see if the drug lowers the number of symptom episodes patients report each day.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Mirabegron
- What this could lead to
- If it works, this could point toward a new treatment option to reduce daily symptoms for people with POTS.
- What could go wrong
- This is a small, early-phase trial with only 36 participants. The drug may not prove more effective than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can two common drugs tame the debilitating symptoms of POTS?
- Long-Term study aims to unlock mystery of joint hypermobility and chronic illness
- Ear zap might tame racing heart in POTS
- Shocking muscles to move: new exercise hope for nerve disease patients
- Skin biopsies may reveal long COVID's hidden nerve damage
- POTS puzzle: scientists probe blood pressure hormone link